Literatur
- 1
Ajani J, Ilson D. et al .
“Paclitaxel in the treatment of carcinoma of the esophagus”.
Semin Oncol.
1995;
22 (3 Suppl 6)
35-40
- 2
Ajani J, Moiseyenko V. et al .
“Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin
and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma:
the V-325 Study Group”.
J Clin Oncol.
2007;
25
3210-3216
- 3
Bleiberg H, Conroy T. et al .
“Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin
alone in advanced squamous cell oesophageal cancer”.
Eur J Cancer.
1997;
33
1216-1220
- 4
Boeck S, Hinke A. et al .
“Importance of performance status for treatment outcome in advanced pancreatic cancer”.
World J Gastroenterol.
2007;
13
224-227
- 5
Brown L, Silverman D. et al .
“Adenocarcinoma of the esophagus and esophagogastric junction in white men in the
United States: alcohol, tobacco, and socioeconomic factors”.
Cancer Causes Control.
1994;
5
333-340
- 6
Burris H, Moore M. et al .
“Improvements in survival and clinical benefit with gemcitabine as first-line therapy
for patients with advanced pancreas cancer: a randomized trial”.
J Clin Oncol.
1997;
15
2403-2413
- 7
Burtness B, Gibson M. et al .
“Phase II trial of docetaxel / irinotecan therapy in metastatic esophageal cancer:
evidence for activity in previously untreated patients”.
J Clin Oncol, ASCO Annual Meeting Proceedings.
2005;
23 No. 16 S
4070
- 8
Casaretto L, Sousa P. et al .
“Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis”.
Braz J Med Biol Res.
2006;
39
431-440
, Epub 2006 Apr 3
- 9
Conroy T, Etienne P. et al .
“Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European
Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative
Group”.
J Clin Oncol.
1996;
14
164-170
- 10
Cunningham D. et al .
“Phase III randomised comparison of Gemcitabine versus gemcitabine plus capecitabine
in patients with advanced pancreatic cancer”.
Eur J Cancer.
2005;
Suppl 3
12
- 11
Cunningham D, Rao S.
“Randomised multicentre phase III study comparing capecitabine with fluorouracil and
oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: The
REAL 2 trial”.
J Clin Oncol, ASCO Annual Meeting Proceedings Part I.
2006;
24 No. 18 S
LBA4017
- 12
Einzig A, Neuberg D. et al .
“Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper
gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern
Cooperative Oncology Group (ECOG) results of protocol E1293”.
Med Oncol.
1996;
13
87-93
- 13
Engstrom P, Lavin P. et al .
“Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma”.
Cancer Treat Rep.
1983;
67
713-715
- 14
Enzinger P, Kulke M. et al .
“A phase II trial of irinotecan in patients with previously untreated advanced esophageal
and gastric adenocarcinoma”.
Dig Dis Sci.
2005;
50
2218-2223
- 15
Enzinger P, Mayer R.
“Esophageal cancer”.
N Engl J Med.
2003;
349
2241-2252
- 16
Ezdinli E, Gelber R. et al .
“Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group
experience”.
Cancer.
1980;
46
2149-2153
- 17 “Krebs in Deutschland. Häufigkeiten und Trends”. In Zusammenarbeit mit dem Robert-Koch-Institut,
5. überarbeitete, aktualisierte Ausgabe. Saarbrücken 2006
- 18
Heath E, Urba S. et al .
“Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma
of the esophagus”.
Invest New Drugs.
2002;
20
95-99
- 19
Heinemann V, Quietzsch D. et al .
“Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine
alone in advanced pancreatic cancer”.
J Clin Oncol.
2006;
24
3946-3952
- 20
Hess V, Salzberg M. et al .
“Combining capecitabone and gemcitabine in patients with advanced pancreatic carcinoma:
a phase I / II trial”.
J Clin Oncol.
2003;
21 (1)
66-68
- 21
Hettiarachchi R, Smorenburg S. et al .
“Do heparins do more than just treat thrombosis? The influence of heparins on cancer
spread”.
Thromb Haemost.
1999;
82
947-952
- 22
Icli F, Akbulut H. et al .
“Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine
combination in advanced pancreatic cancer”.
J Surg Oncol.
2006;
27
27
- 23
Ilson D.
“Phase II trial of weekly irinotecan / cisplatin in advanced esophageal cancer”.
Oncology (Williston Park).
2004;
18 (14 Suppl 14)
22-25
- 24
Ilson D, Forastiere A. et al .
“A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma
of the esophagus”.
Cancer J.
2000;
6
316-323
- 25
Ilson D, Wadleigh R. et al .
“Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer”.
Ann Oncol.
2007;
18
898-902
, Epub 2007 Mar 9
- 26
Janmaat M, Gallegos-Ruiz M. et al .
“Predictive factors for outcome in a phase II study of gefitinib in second-line treatment
of advanced esophageal cancer patients”.
J Clin Oncol.
2006;
24
1612-1619
- 27
Kang Y, Kang W. et al .
“Randomized phase III trial of capecitabine / cisplatin (XP) vs. continuous infusion
of 5-FU / cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric
cancer (AGC): efficacy and safety results”.
J Clin Oncol, ASCO Annual Meeting Proceedings Part I.
2006;
24 No. 18 S
LBA4018
- 28
Kelsen D, Ginsberg R. et al .
“Chemotherapy followed by surgery compared with surgery alone for localized esophageal
cancer”.
N Engl J Med.
1998;
339
1979-1984
- 29
Kindler H, Niedzwiecki D. Cancer and Leukemia Group B .
“A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G)
plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced
pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB)”.
J Clin Oncol ASCO Annual Meeting Proceedings Part I.
2007;
25 No. 18 S
4508
- 30
Lordick F, Lorenzen S. et al .
“Cetuximab plus weekly oxaliplatin / 5FU / FA (FUFOX) in 1st line metastatic gastric
cancer. Final results from a multicenter phase II study of the AIO upper GI study
group”.
J Clin Oncol, ASCO Annual Meeting Proceedings Part I.
2007;
25 No. 18 S
4526
- 31
Louvet C, Hincke A. et al .
“Increased survival using platinum analog combined with gemcitabine as compared to
gemciatbien single agent in advanced pancreatic cancer: Pooled analysis of tow randomised
trials, the GERCOR / GISCAD Intergroup Study and a German multicenter Study”.
J Clin Oncol.
2006;
24 No. 18 S
4003
- 32
Louvet C, Labianca R. et al .
“Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally
advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III
trial”.
J Clin Oncol.
2005;
23
3509-3516
- 33
Lutz M, Wilke H. et al .
“Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU
/ FA), or HD-FU / FA plus biweekly cisplatin in advanced gastric cancer: randomized
phase II trial 40953 of the European Organisation for Research and Treatment of Cancer
Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie”.
J Clin Oncol.
2007;
25
2580-2585
- 34
Millela M, Carlini A. et al .
“Gemcitabine-based polychemotherapy for advanced pancreatic cancer: Is it ready for
prime time? A pooled analysis of 3 682 patients enrolled in 12 phase II trials”.
J Clin Oncol, ASCO Annual Meeting Proceedings Part I.
2006;
24 No. 18 S
4118
- 35
Moore M, Goldstein D. et al .
“Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced
pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical
Trials Group”.
J Clin Oncol.
2007;
25
1960-1966
, Epub 2007 Apr 23
- 36
Muro K, Hamaguchi T. et al .
“A phase II study of single-agent docetaxel in patients with metastatic esophageal
cancer”.
Ann Oncol.
2004;
15
955-959
- 37
Narahara H, Koizumi W. et al .
“Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for
advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in
RCT in the treatment for stomach cancer”.
J Clin Oncol, ASCO Annual Meeting Proceedings Part I.
2007;
25 No. 18 S
4514
- 38
Pelzer U, Hilbig A. et al .
“ A prospective, randomized trial of simultaneous pancreatic cancer treatment with
enoxaparin and chemotherapy (PROSPECT - CONKO 004)”.
J Clin Oncol, ASCO Annual Meeting Proceedings Part I.
2006;
24 No. 18 S
4110
- 39
Pinto C, Di Fabio F. et al .
“Phase II study of cetuximab in combination with FOLFIRI in patients with untreated
advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)”.
Ann Oncol.
2007;
18
510-517
, Epub 2006 Dec 12
- 40
Rickles F, Edwards R.
“Activation of blood coagulation in cancer: Trousseau's syndrome revisited”.
Blood.
1983;
62
14-31
- 41
Ross P, Nicolson M. et al .
“Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion
fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric
cancer”.
J Clin Oncol.
2002;
20
1996-2004
- 42
Sener S, Fremgen A. et al .
“Pancreatic cancer: a report of treatment and survival trends for 100 313 patients
diagnosed from 1985-1995, using the National Cancer Database”.
J Am Coll Surg.
1999;
189
1-7
- 43
Shah M, Ramanathan R. et al .
“Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients
with metastatic gastric or gastroesophageal junction adenocarcinoma”.
J Clin Oncol.
2006;
24
5201-5206
- 44
Shen V, Pollak E.
“Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified”?.
South Med J.
1980;
73
841-843
- 45
Tebbutt N, Sourjina T. et al .
“ATTAX: Randomised phase II study evaluating weekly docetaxel-based chemotherapy combinations
in advanced esophago-gastric cancer, final results of an AGITG trial”.
J Clin Oncol, ASCO Annual Meeting Proceedings Part I.
2007;
25 No. 18 S
4528
- 46
Van Cutsem E, Moiseyenko V. et al .
“Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin
and fluorouracil as first-line therapy for advanced gastric cancer: a report of the
V325 Study Group”.
J Clin Oncol.
2006;
24
4991-4997
- 47
Wagner A, Grothe W. et al .
“Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based
on aggregate data”.
J Clin Oncol.
2006;
24
2903-2909
- 48
Webb A, Cunningham D. et al .
“Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil,
doxorubicin, and methotrexate in advanced esophagogastric cancer”.
J Clin Oncol.
1997;
15
261-267
- 49
Whittington R, Close H.
“Clinical Experience with Mitomycin”.
Cancer Chem Rep.
1970;
54
195
PD Dr. H. Oettle
Dr. M. Sinn
Charité - Universitätsmedizin Berlin · CharitéCentrum für Tumormedizin · Med. Klinik
m. S. Hämatologie / Onkologie
Augustenburger Platz 1
13353 Berlin
Phone: +49 / 30 / 4 50 / 55 32 22
Fax: +49 / 30 / 4 50 / 55 39 59
Email: helmut.oettle@charite.de
Email: marianne.sinn@charite.de
